{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:21:08Z","timestamp":1790702468573,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00280-019-03806-5","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T21:26:26Z","timestamp":1551216386000},"page":"881-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report"],"prefix":"10.1007","volume":"83","author":[{"given":"Emmanuelle","family":"Couty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8147-1298","authenticated-orcid":false,"given":"Alexis","family":"Vallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Sotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarra","family":"Ouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max-Adrien","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Espenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Rancoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Ben Mrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Biron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Langrand-Escure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Magn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"3806_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","volume":"63","author":"C Garbe","year":"2016","unstructured":"Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, Grob J-J, Malvehy J, Newton-Bishop J, Stratigos AJ, Pehamberger H, Eggermont AM, European Dermatology Forum (EDF) et al (2016) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline\u2014update 2016. Eur J Cancer Oxf Engl 1990 63:201\u2013217. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.05.005","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"3806_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/jdv.14064","volume":"31","author":"B Guillot","year":"2017","unstructured":"Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, Hindie E, Jouary T, Lassau N, Mirabel X, Piperno Neumann S, De Raucourt S, Vanwijck R (2017) French updated recommendations in Stage I to III melanoma treatment and management. J Eur Acad Dermatol Venereol 31:594\u2013602. \n                    https:\/\/doi.org\/10.1111\/jdv.14064","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3806_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.6004\/jnccn.2016.0101","volume":"14","author":"DG Coit","year":"2016","unstructured":"Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V et al (2016) NCCN guidelines insights: melanoma, version 3.2016. J Natl Compr Cancer Netw 14:945\u2013958","journal-title":"J Natl Compr Cancer Netw"},{"key":"3806_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B, Atkinson V, Liszkay G, Di Giacomo AM, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248\u20131260. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X","journal-title":"Lancet Oncol"},{"key":"3806_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30\u201339. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1412690","journal-title":"N Engl J Med"},{"key":"3806_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandal\u00e0 M et al (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28:1631\u20131639. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx176","journal-title":"Ann Oncol"},{"key":"3806_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"3806_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebb\u00e9 C et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"3806_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853\u20131862. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X","journal-title":"Lancet"},{"key":"3806_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"3806_CR11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob J-J, Davidson N, Richards J, Maio M et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517\u20132526. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1104621","journal-title":"N Engl J Med"},{"key":"3806_CR12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J et al (2015) Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol 16:1049\u20131060. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00187-4","journal-title":"Lancet Oncol"},{"key":"3806_CR13","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1002\/cncr.24627","volume":"115","author":"S Agrawal","year":"2009","unstructured":"Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT (2009) The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 115:5836\u20135844. \n                    https:\/\/doi.org\/10.1002\/cncr.24627","journal-title":"Cancer"},{"key":"3806_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/CMR.0000000000000292","volume":"26","author":"HH Danish","year":"2016","unstructured":"Danish HH, Patel KR, Switchenko JM, Gillespie TW, Jhaveri J, Chowdhary M, Abugideiri M, Delman KA, Lawson DH, Khan MK (2016) The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res 26:595\u2013603. \n                    https:\/\/doi.org\/10.1097\/CMR.0000000000000292","journal-title":"Melanoma Res"},{"key":"3806_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.canrad.2014.05.007","volume":"18","author":"J Thariat","year":"2014","unstructured":"Thariat J, Kirova Y, Milano G, Mornex F (2014) [Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations]. Cancer Radiother 18:270\u2013279. \n                    https:\/\/doi.org\/10.1016\/j.canrad.2014.05.007","journal-title":"Cancer Radiother"},{"key":"3806_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ijrobp.2016.01.038","volume":"95","author":"CJ Anker","year":"2016","unstructured":"Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM (2016) Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 95:632\u2013646. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2016.01.038","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3806_CR17","unstructured":"Shargel L, Wu-Pong S, Yu ABC (2015) Applied biopharmaceuticals & pharmacokinetics, 7th edn. McGraw Hill Medical"},{"key":"3806_CR18","unstructured":"European Medicines Agency (EMA); Find Medicines. Human Medicines [Internet]. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124\n                    \n                  . Accessed 20 Jan 2019"},{"key":"3806_CR19","unstructured":"Common Terminology Criteria for Adverse Events v4.0 (CTCAE) [Internet]. \n                    http:\/\/www.hrc.govt.nz\/sites\/default\/files\/CTCAE%20manual%20-%20DMCC.pdf\n                    \n                  . Accessed 20 Jan 2019"},{"key":"3806_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-014-0305-4","author":"M-AS Kress","year":"2015","unstructured":"Kress M-AS, Jensen RE, Tsai H-T, Lobo T, Satinsky A, Potosky AL (2015) Radiation therapy at the end of life: a population-based study examining palliative treatment intensity. Radiat Oncol Lond Engl [Internet]. \n                    https:\/\/doi.org\/10.1186\/s13014-014-0305-4\n                    \n                  \n                           (cited 2019 Jan 23)","journal-title":"Radiat Oncol Lond Engl [Internet]"},{"key":"3806_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1200\/JCO.2012.45.0585","volume":"31","author":"BA Guadagnolo","year":"2013","unstructured":"Guadagnolo BA, Liao K-P, Elting L, Giordano S, Buchholz TA, Tina Shih Y-C (2013) Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol 31:80\u201387. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.45.0585","journal-title":"J Clin Oncol"},{"key":"3806_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2016.12.003","volume":"110","author":"S Espenel","year":"2017","unstructured":"Espenel S, Vallard A, Rancoule C, Garcia M-A, Guy J-B, Chargari C, Deutsch E, Magn\u00e9 N (2017) Melanoma: last call for radiotherapy. Crit Rev Oncol Hematol 110:13\u201319. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2016.12.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"3806_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/CAD.0000000000000349","volume":"27","author":"J Langrand-Escure","year":"2016","unstructured":"Langrand-Escure J, Vallard A, Rivoirard R, M\u00e9ry B, Guy J-B, Espenel S, Trone J-C, Ben Mrad M, Diao P, Rancoule C, Suchaud J-P, Fournel P, Guillot A et al (2016) Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report. Anticancer Drugs 27:427\u2013432. \n                    https:\/\/doi.org\/10.1097\/CAD.0000000000000349","journal-title":"Anticancer Drugs"},{"key":"3806_CR24","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1684\/ejd.2013.2193","volume":"23","author":"L Peuvrel","year":"2013","unstructured":"Peuvrel L, Ruellan A-L, Thillays F, Quereux G, Brocard A, Saint-Jean M, Aumont M, Drouet F, Dreno B (2013) Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23:879\u2013881. \n                    https:\/\/doi.org\/10.1684\/ejd.2013.2193","journal-title":"Eur J Dermatol"},{"key":"3806_CR25","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.prro.2012.11.012","volume":"3","author":"TM Churilla","year":"2013","unstructured":"Churilla TM, Chowdhry VK, Pan D, de la Roza G, Damron T, Lacombe MA (2013) Radiation-induced dermatitis with vemurafenib therapy. Pract Radiat Oncol 3:e195\u2013e198. \n                    https:\/\/doi.org\/10.1016\/j.prro.2012.11.012","journal-title":"Pract Radiat Oncol"},{"key":"3806_CR26","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1200\/JCO.2013.49.0565","volume":"34","author":"T Pulvirenti","year":"2016","unstructured":"Pulvirenti T, Hong A, Clements A, Forstner D, Suchowersky A, Guminski A, McNeil C, Hersey P, Fogarty G, Kefford R, Long GV, Wang W (2016) Acute radiation skin toxicity associated with BRAF inhibitors. J Clin Oncol 34:e17\u2013e20. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.49.0565","journal-title":"J Clin Oncol"},{"key":"3806_CR27","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/j.jaad.2013.10.046","volume":"70","author":"M Saco","year":"2014","unstructured":"Saco M, Mitchell C (2014) Severe radiation dermatitis associated with concomitant vemurafenib therapy in a patient with metastatic melanoma. J Am Acad Dermatol 70:e135\u2013e136. \n                    https:\/\/doi.org\/10.1016\/j.jaad.2013.10.046","journal-title":"J Am Acad Dermatol"},{"key":"3806_CR28","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/j.prro.2013.10.007","volume":"4","author":"JB Wallach","year":"2014","unstructured":"Wallach JB, Rietschel P, Kalnicki S, Fox JL (2014) BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. Pract Radiat Oncol 4:e213\u2013e216. \n                    https:\/\/doi.org\/10.1016\/j.prro.2013.10.007","journal-title":"Pract Radiat Oncol"},{"key":"3806_CR29","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1200\/JCO.2012.44.4265","volume":"31","author":"I Satzger","year":"2013","unstructured":"Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R (2013) Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 31:e220\u2013e222. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.44.4265","journal-title":"J Clin Oncol"},{"key":"3806_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00066-013-0474-3","volume":"190","author":"B Schulze","year":"2014","unstructured":"Schulze B, Meissner M, Wolter M, R\u00f6del C, Weiss C (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 190:229\u2013232. \n                    https:\/\/doi.org\/10.1007\/s00066-013-0474-3","journal-title":"Strahlenther Onkol"},{"key":"3806_CR31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamadermatol.2013.4200","volume":"149","author":"L Boussemart","year":"2013","unstructured":"Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, Mateus C, Deutsch E, Robert C (2013) Vemurafenib and radiosensitization. JAMA Dermatol 149:855\u2013857. \n                    https:\/\/doi.org\/10.1001\/jamadermatol.2013.4200","journal-title":"JAMA Dermatol"},{"key":"3806_CR32","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","volume":"31","author":"CJ Anker","year":"2013","unstructured":"Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RHI, Noyes RD, Shrieve DC, Grossmann KF (2013) Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 31:e283\u2013e287. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.44.7755","journal-title":"J Clin Oncol"},{"key":"3806_CR33","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00066-014-0698-x","volume":"190","author":"R Merten","year":"2014","unstructured":"Merten R, Hecht M, Haderlein M, Distel L, Fietkau R, Heinzerling L, Semrau S (2014) Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. Strahlenther Onkol 190:1169\u20131172. \n                    https:\/\/doi.org\/10.1007\/s00066-014-0698-x","journal-title":"Strahlenther Onkol"},{"key":"3806_CR34","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","volume":"26","author":"M Hecht","year":"2015","unstructured":"Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G et al (2015) Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol 26:1238\u20131244. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv139","journal-title":"Ann Oncol"},{"key":"3806_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","volume":"113","author":"A Narayana","year":"2013","unstructured":"Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Parker EC, Ott PA, Pavlick AC (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113:411\u2013416. \n                    https:\/\/doi.org\/10.1007\/s11060-013-1127-1","journal-title":"J Neurooncol"},{"key":"3806_CR36","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.2147\/OTT.S119428","volume":"9","author":"M Chowdhary","year":"2016","unstructured":"Chowdhary M, Patel KR, Danish HH, Lawson DH, Khan MK (2016) BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy. OncoTargets Ther 9:7149\u20137159. \n                    https:\/\/doi.org\/10.2147\/OTT.S119428","journal-title":"OncoTargets Ther"},{"key":"3806_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.radonc.2010.12.017","volume":"98","author":"MJ Sambade","year":"2011","unstructured":"Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98:394\u2013399. \n                    https:\/\/doi.org\/10.1016\/j.radonc.2010.12.017","journal-title":"Radiother Oncol"},{"key":"3806_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/1078155215572930","volume":"22","author":"MK Ery\u0131lmaz","year":"2016","unstructured":"Ery\u0131lmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Ba\u015fsorgun I, Co\u015fkun H (2016) Ipilimumab may increase the severity of cutaneous toxicity related to radiotherapy. J Oncol Pharm Pract 22:533\u2013536. \n                    https:\/\/doi.org\/10.1177\/10781550215572930","journal-title":"J Oncol Pharm Pract"},{"key":"3806_CR39","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1016\/j.ejca.2012.05.016","volume":"48","author":"S Du Four","year":"2012","unstructured":"Du Four S, Wilgenhof S, Duerinck J, Michotte A, Van Binst A, De Ridder M, Neyns B (2012) Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer 48:3045\u20133051. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2012.05.016","journal-title":"Eur J Cancer"},{"key":"3806_CR40","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368\u2013375. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3806_CR41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/PPO.0000000000000236","volume":"23","author":"FE Escorcia","year":"2017","unstructured":"Escorcia FE, Postow MA, Barker CA (2017) Radiotherapy and immune checkpoint blockade for melanoma: a promising combinatorial strategy in need of further investigation. Cancer J Sudbury Mass 23:32\u201339. \n                    https:\/\/doi.org\/10.1097\/PPO.0000000000000236","journal-title":"Cancer J Sudbury Mass"},{"key":"3806_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gore.2016.04.001","volume":"16","author":"MB Schiavone","year":"2016","unstructured":"Schiavone MB, Broach V, Shoushtari AN, Carvajal RD, Alektiar K, Kollmeier MA, Abu-Rustum NR, Leitao MM (2016) Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep 16:42\u201346. \n                    https:\/\/doi.org\/10.1016\/j.gore.2016.04.001","journal-title":"Gynecol Oncol Rep"},{"key":"3806_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1158\/2326-6066.CIR-13-0082","volume":"1","author":"CA Barker","year":"2013","unstructured":"Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD (2013) Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 1:92\u201398. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0082","journal-title":"Cancer Immunol Res"},{"key":"3806_CR44","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00280-018-3557-0","volume":"81","author":"M Nomura","year":"2018","unstructured":"Nomura M, Otsuka A, Yoshimura M, Nonomura Y, Kaku Y, Matsumoto S, Muto M (2018) Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab. Cancer Chemother Pharmacol 81:823\u2013827. \n                    https:\/\/doi.org\/10.1007\/s00280-018-3557-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"3806_CR45","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/annonc\/mdv622","volume":"27","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Stallworth DG, Kim Y, Johnstone PS, Harrison LB, Caudell JJ, Yu HHM, Etame AB, Weber JS, Gibney GT (2016) Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27:434\u2013441. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv622","journal-title":"Ann Oncol"},{"key":"3806_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.adro.2018.04.015","volume":"3","author":"NP Amin","year":"2018","unstructured":"Amin NP, Zainib M, Parker SM, Agarwal M, Mattes MD (2018) Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. Adv Radiat Oncol 3:399\u2013404. \n                    https:\/\/doi.org\/10.1016\/j.adro.2018.04.015","journal-title":"Adv Radiat Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03806-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T19:13:12Z","timestamp":1582657992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03806-5"}},"subtitle":["Radiation\/systemic drug combo in metastatic melanoma"],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3806"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03806-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare having no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}